Medical services stock is topping in a buy zone of a cup base. The cancer testing name is showing smaller losses
Research
Medical Services Name Tests For Colon Cancer. Natera Stock Hits A High.
Licensing
01:36 PM ET 06/29/2026
Natera (NTRA) stock got a boost from an analyst's price target hike and new partnership news, lifting shares to a record high Monday. The medical services stock had a powerful breakout last week on the company's positive news on its colon cancer test, and is in the buy zone of a cup base. Natera's constructive chart action and its 3-year…
Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.
Natera stock surged Friday after reporting "blowout volume" for its cancer-detecting blood test, Signatera.
Cancer test name Natera stock is in a buy zone above a cup base ahead of second-quarter results due Thursday.
Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
Natera shares rocketed Friday as the company reported a strong revenue beat.
Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch by 2026.
